Literature DB >> 17107777

High throughput screening of protein formulation stability: practical considerations.

Martinus A H Capelle1, Robert Gurny, Tudor Arvinte.   

Abstract

The formulation of protein drugs is a difficult and time-consuming process, mainly due to the complexity of protein structure and the very specific physical and chemical properties involved. Understanding protein degradation pathways is essential for the success of a biopharmaceutical drug. The present review concerns the application of high throughput screening techniques in protein formulation development. A protein high throughput formulation (HTF) platform is based on the use of microplates. Basically, the HTF platform consists of two parts: (i) sample preparation and (ii) sample analysis. Sample preparation involves automated systems for dispensing the drug and the formulation ingredients in both liquid and powder form. The sample analysis involves specific methods developed for each protein to investigate physical and chemical properties of the formulations in microplates. Examples are presented of the use of protein intrinsic fluorescence for the analysis of protein aqueous properties (e.g., conformation and aggregation). Different techniques suitable for HTF analysis are discussed and some of the issues concerning implementation are presented with reference to the use of microplates.

Mesh:

Substances:

Year:  2006        PMID: 17107777     DOI: 10.1016/j.ejpb.2006.09.009

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  24 in total

1.  Modifications of therapeutic proteins: challenges and prospects.

Authors:  Nigel Jenkins
Journal:  Cytotechnology       Date:  2007-05-25       Impact factor: 2.058

2.  The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Authors:  Sunday A Shoyele; Neeraj Sivadas; Sally-Ann Cryan
Journal:  AAPS PharmSciTech       Date:  2011-01-27       Impact factor: 3.246

3.  An Efficient and Rapid Method to Monitor the Oxidative Degradation of Protein Pharmaceuticals: Probing Tyrosine Oxidation with Fluorogenic Derivatization.

Authors:  Rupesh Bommana; Olivier Mozziconacci; Y John Wang; Christian Schöneich
Journal:  Pharm Res       Date:  2017-04-18       Impact factor: 4.200

4.  High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants.

Authors:  Sean M McClure; Patrick L Ahl; Jeffrey T Blue
Journal:  Pharm Res       Date:  2018-03-05       Impact factor: 4.200

5.  Modification of the kinetic stability of immunoglobulin G by solvent additives.

Authors:  Jonas V Schaefer; Erik Sedlák; Florian Kast; Michal Nemergut; Andreas Plückthun
Journal:  MAbs       Date:  2018-04-25       Impact factor: 5.857

Review 6.  Chemical denaturation as a tool in the formulation optimization of biologics.

Authors:  Ernesto Freire; Arne Schön; Burleigh M Hutchins; Richard K Brown
Journal:  Drug Discov Today       Date:  2013-06-21       Impact factor: 7.851

7.  Temperature stability of proteins: Analysis of irreversible denaturation using isothermal calorimetry.

Authors:  Arne Schön; Benjamin R Clarkson; Maria Jaime; Ernesto Freire
Journal:  Proteins       Date:  2017-08-08

Review 8.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

9.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

10.  Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Steven A Berkowitz; Damian Houde
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-29       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.